These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11908767)

  • 21. Hyponatraemia associated with lopinavir--ritonavir?
    Roberts MT; Aliyu SH
    Int J Infect Dis; 2007 Jan; 11(1):83-4. PubMed ID: 16574455
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmacogenetics of antiretroviral therapy 2008: toward personalized treatment?].
    Vidal Marsal F
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():1-3. PubMed ID: 18680689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 12th annual HIV drug guide.
    Diaz-Linares M; Vázquez E; Gallant J; Delaney M
    Posit Aware; 2008; 19(1):19-48. PubMed ID: 18546577
    [No Abstract]   [Full Text] [Related]  

  • 27. 13th annual HIV drug guide.
    Djuricich P; Vázquez E
    Posit Aware; 2009; 20(2):28-55. PubMed ID: 19280745
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic abnormalities are associated with HIV and treatment.
    Murphy MJ
    Fac Notes (New Orleans La); 1999; 11(1):6-7. PubMed ID: 11810889
    [No Abstract]   [Full Text] [Related]  

  • 29. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV and pharmacogenomics in 2007.
    Khoo S
    Pharmacogenomics; 2007 Jan; 8(1):25-7. PubMed ID: 17187506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 32. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 33. [Highly effective and tolerable protease inhibitor. New trump card against HIV].
    MMW Fortschr Med; 2003 Jan; 145(1-2):55. PubMed ID: 12638446
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug interactions. Interactions with TMC114 and TMC125.
    TreatmentUpdate; 2006; 18(3):8-9. PubMed ID: 17211920
    [No Abstract]   [Full Text] [Related]  

  • 35. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

  • 36. The longer the better? Four years of durable, initially boosted protease treatment.
    Katzenstein D
    AIDS; 2004 Mar; 18(5):811-3. PubMed ID: 15075518
    [No Abstract]   [Full Text] [Related]  

  • 37. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients.
    De Wit S; Boulmé R; Poll B; Schmit JC; Clumeck N
    AIDS; 2004 Nov; 18(17):2330-1. PubMed ID: 15577548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity of antiretroviral therapy and implications for drug development.
    Carr A
    Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
    [No Abstract]   [Full Text] [Related]  

  • 39. Contemporary protease inhibitors and cardiovascular risk.
    Lundgren J; Mocroft A; Ryom L
    Curr Opin Infect Dis; 2018 Feb; 31(1):8-13. PubMed ID: 29232276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era.
    MacArthur RD; DuPont HL
    Clin Infect Dis; 2012 Sep; 55(6):860-7. PubMed ID: 22700829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.